Eli Lilly and Co (LTS:0Q1G) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0Q1G Eli Lilly and Co LTS:0Q1G
96 GF Score
Price CHF680.00
GF Value CHF827.70
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0Q1G
96GF Score
Eli Lilly and Co LTS:0Q1G
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (LTS:0Q1G) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF680.00 is trading 17.8% below its estimated GF Value™ of CHF827.70.

Key valuation signals for LTS:0Q1G:

  • Short Ratio:
  • GF Value™: CHF827.70 vs. price of CHF680.00 (17.8% below fair value)
  • GF Score™: 96/100 with 4 warning signs

No single metric tells the full story. See the LTS:0Q1G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
96GF Score

Get the complete analysis for LTS:0Q1G

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF680.00
Price
CHF827.70
GF Value